COOH-terminal Truncations Promote Proteasome-dependent Degradation of Mature Cystic Fibrosis Transmembrane Conductance Regulator from Post-Golgi Compartments

Mohamed Benharouga,‡ Martin Haardt,‡ Norbert Kartner,§ and Gergely L. Lukacs‡

*Program in Lung and Cell Biology, The Hospital for Sick Children, Toronto M5G 1X8, Ontario, Canada; and ‡Department of Laboratory Medicine and Pathobiology, and §Department of Pharmacology, University of Toronto, Toronto M5G 1X8, Ontario, Canada

Abstract. Impaired biosynthetic processing of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR), a cAMP-regulated chloride channel, constitutes the most common cause of CF. Recently, we have identified a distinct category of mutation, caused by premature stop codons and frameshift mutations, which manifests in diminished expression of COOH-terminally truncated CFTR at the cell surface. Although the biosynthetic processing and plasma membrane targeting of truncated CFTRs are preserved, the turnover of the complex-glycosylated mutant is sixfold faster than its wild-type (wt) counterpart. Destabilization of the truncated CFTR coincides with its enhanced susceptibility to proteasome-dependent degradation from post-Golgi compartments globally, and the plasma membrane specifically, determined by pulse–chase analysis in conjunction with cell surface biotinylation. Proteolytic cleavage of the full-length complex-glycosylated wt and degradation intermediates derived from both T70 and wt CFTR requires endolysosomal proteases. The enhanced protease sensitivity in vitro and the decreased thermostability of the complex-glycosylated T70 CFTR in vivo suggest that structural destabilization may account for the increased proteasome susceptibility and the short residence time at the cell surface. These in turn are responsible, at least in part, for the phenotypic manifestation of CF. We propose that the proteasome-ubiquitin pathway may be involved in the peripheral quality control of other, partially unfolded membrane proteins as well.

Key words: cystic fibrosis • lysosomal proteolysis • structural destabilization • functional complementation • ubiquitination

Introduction

Newly synthesized secretory and membrane proteins must attain their native conformation spontaneously or with the assistance of ER-resident and cytosolic chaperones before their export from the ER. The ER quality control mechanism assures that functionally incompetent, misfolded, or unassembled oligomeric proteins are retained and targeted for proteolysis via the ER-associated degradation (ERAD) pathway (Hurtley and Helnìus, 1989; Brodsky and McCracken, 1997; Bonifacino and Weismann, 1998; Ellgaard et al., 1999; Wickner et al., 1999). The ERAD involves the recognition, dislocation, and proteolysis of misfolded polypeptides by the 26S proteasome, a multicatalytic enzyme complex localized to the cytoplasm and nucleus (Baumeister et al., 1998; Bonifacino and Weismann, 1998; Brodsky and McCracken, 1999; Plemper and Wolf, 1999). The ATP-dependent cleavage process is facilitated by multiple ubiquitin attachments to the e-amino groups of lysine residues of the substrate and catalyzed by a cascade of enzymatic reactions involving ubiquitin-activating (E1) and conjugating (E2) enzymes in addition to ubiquitin-protein ligases (E3) (Hershko and Ciechanover, 1998). Trafficking defects have been recognized as the underlying mechanism in a growing number of genetic diseases, including cystic fibrosis (CF), diabetes insipidus, and α1-antitrypsin deficiency (Thomas et al., 1995; Bonifacino and Weismann, 1998; Hershko and Ciechanover, 1998; Aridor and Balch, 1999; Kopito, 1999; Schwartz and Ciechanover, 1999). CF, the most prevalent recessive genetic disorder in the caucasian population, is caused by the dysfunction of the CF transmembrane conductance regulator (CFTR), a member of the ATP-binding cassette transport protein family (Riordan et al., 1989; Rommens et al., 1989). CFTR
is a cAMP-stimulated Cl\(^{-}\) channel, residing predominantly at the cell surface and, less abundantly, in the endosomal compartment (Bradbury, 1999). The channel consists of two homologous halves, each comprised of six transmembrane helices and a nucleotide binding domain (NBD1 and NBD2), which are connected by the regulatory domain (Riordan et al., 1989). This complex, multidomain structure conceivably renders the posttranslational folding of wild-type (wt) CFTR inefficient. Approximately 70% of the newly synthesized wt CFTR is trapped in the ER as core-glycosylated folding intermediate (apparent molecular weight \(\sim 150,000\)) and degraded with a \(t_{1/2}\) of \(\sim 30\) min by the ERAD. Proteasome activity is responsible, at least in part, for the degradation of the co- and posttranslationally ubiquitinated and incompletely folded CFTR at the ER (Jensen et al., 1995; Ward et al., 1995; Xiong et al., 1999). However, inhibition of proteasomes has failed to promote the processing of core-glycosylated wt as well as the \(\Delta F508\) CFTR (Jensen et al., 1995; Ward et al., 1995).

Only 20–30% of the newly synthesized CFTR enters the secretory pathway after its ATP-dependent conformational maturation (Lukacs et al., 1994; Zhang et al., 1998) assisted by cytosolic and ER-resident chaperones (Yang et al., 1993; Pind et al., 1994; Loo et al., 1998; Meacham et al., 1999). Processing of the high mannose type N-linked glycan to complex type oligosaccharides in the cis medial Golgi region is reflected by a decreased electrophoretic mobility (\(\sim 180\) kD), providing a convenient method to monitor the trafficking of the CFTR (Cheng et al., 1990; Lukacs et al., 1994; Ward and Kopito, 1994; Riordan, 1999). Not only does the folded complex-glycosylated CFTR have a slow turnover in vivo (\(t_{1/2} < 12\) h), but it also displays a conformation which is more resistant to proteolysis in vitro (Zhang et al., 1998). The posttranslational folding or conformational maturation of CFTR is independent of ER to Golgi vesicular transport, implying that complex glycosylation is not a prerequisite to attain the native conformation (Lukacs et al., 1994; Ward and Kopito, 1994; Zhang et al., 1998).

The majority of CF-associated point mutations, including the most common, \(\Delta F508\) CFTR, impair biosynthetic processing by disrupting posttranslational folding at the ER (Welsh and Smith, 1993; Zielenks and Tsui, 1995; Riordan, 1999). Recently, we have identified a mechanistically distinct category of mutation, caused by premature termination and frameshift mutations in the CF gene (Haardt et al., 1999). Although the ER processing of these COOH-terminally truncated CFTR variants missing their last 70–82 amino acid residues (T70 and T82 CFTR) is similar to that of the wt form, the biological half-life of the complex-glycosylated mutants is sixfold shorter than their wt counterpart (Haardt et al., 1999). Although the proteolytic elimination mechanism of the processing mutants entrapped in the ER has been extensively studied (Welsh and Smith, 1993; Kopito, 1999; Riordan, 1999), the cellular processes responsible for the short residence time of the truncated CFTR in post-Golgi compartments remained obscure.

Here we show that deletion of the COOH terminus renders the complex-glycosylated truncated CFTR highly susceptible to proteasome-dependent proteolysis at post-Golgi compartments, including the plasma membrane. Structural destabilization, demonstrated by increased pro tease susceptibility in vitro and diminished thermostability of the complex-glycosylated mutants in vivo, may serve as signal for premature proteolysis. In contrast, lysosomal proteolysis appears to represent the rate-limiting step in the degradation of the complex-glycosylated wt CFTR. These results reveal a novel aspect of the proteasome-dependent degradation pathway in the elimination of non-native CFTR after its escape from the ER quality control.

### Materials and Methods

#### Plasmids

The influenza hemagglutinin (HA) epitope was attached to the NH\(_{2}\) terminus ubiquitin using PCR mutagenesis and the cDNA of the yeast ubiquitin as template (provided by Dr. R. Haguenauer-Tsapis, Jacques Monod, University of Paris VII, Paris, France). To generate the Tac-Lamp1 chimera, the extracellular and transmembrane segment of the interleukin 2 receptor (Tac) was fused to the cytoplasmic tail of Lamp-1. The constructs were sequenced to verify that no errors had been introduced. The cDNA, encoding for the Tac and Tac-TCR\(_{\alpha}\), were provided by Dr. J. Bonifacino (National Institutes of Health, Bethesda, MD). Tac, Tac-TCR\(_{\alpha}\), and Tac-Lamp1 were stably transfected in BHK-21 cells using the pNUT expression cassette (Haardt et al., 1999).

#### Cell Lines and Transfections

Mixtures of stably transfected BHK-21 cells expressing wt, truncated CFTR (missing the last 26, 70, 82, and 98 amino acid residues: T26, T70, T82, and T98 CFTR, respectively) or Tac, Tac-TCR\(_{\alpha}\), and Tac-Lamp1, were generated and maintained as described (Haardt et al., 1999). Intestinal epithelia (T84 and CaCo-2) expressing endogenous CFTR were cultured as described (Lukacs et al., 1993, 1994). COS-1 cells were transiently transfected with Lipofectamine (Haardt et al., 1999).

#### Electrophoresis and Immunoblotting

Cells were washed with ice-cold PBS and lysed in RIPA buffer (150 mM NaCl, 20 mM Tris-HCl, 1% Triton X-100, 0.1% SDS, and 0.5% sodium deoxycholate, pH 8.0), containing 5 \(\mu\)g/ml of leupeptin and pepstatin A, 10 mM iodoacetamide, and 1 mM PMSF at 4°C. Nuclei and unbroken cells were removed by centrifugation (15,000 \(g\), 15 min at 4°C). Proteins were denatured in Laemmli sample buffer, separated by SDS-PAGE, and transferred to nitrocellulose membrane. Immunoblotting was performed as described previously, using mouse monoclonal L12B4 and M3A7 anti-CFTR antibodies (Abs; Kartner et al., 1992), mouse monoclonal anti-HA (Covance), and antiubiquitin Abs (Santa Cruz Biotechnology, Inc.; Lukacs et al., 1994). Primary Abs were visualized by horseradish peroxide-conjugated sheep anti-mouse IgG and enhanced chemiluminescence (ECL, Western blot kit; Amersham Pharmacia Biotech).

#### Metabolic Pulse–Chase Labeling and Immunoprecipitation

BHK or COS-1 cells were pulse labeled in the presence of \(^{35}\)S-methionine and \(^{35}\)S-cysteine (0.1–0.25 \(\mu\)Ci/\(\mu\)l) and chased in complete medium for the specified time at 37°C. CFTR was immunoprecipitated with a mixture of M3A7 and L12B4 anti-CFTR Abs, as described (Lukacs et al., 1994). The duration of pulse and chase periods and withdrawals of samples are indicated on schematic figures. Radioactivity associated with CFTR was visualized by fluorography and quantified by PhosphorImager (PD) using the ImageQuant software (Haardt et al., 1999).

#### Cell Surface Biotinylation

To determine the expression levels of wt and truncated CFTR at the cell surface and early endosomes, BHK cells were metabolically labeled to steady state overnight and rinsed with H buffer (154 mM NaCl, 10 mM Hepes, 3 mM KCl, 1 mM MgCl\(_2\), 0.1 mM CaCl\(_2\), 10 mM glucose, pH 7.6). Cells were biotinylated in the presence of 1 mg/ml sulphosuccinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate (EZ-Link sulfo-NHS-SS-biotin; Pierce Chemical Co.) in H buffer at 37°C (Lukacs et al., 1997). Cells were...
washed with ice-cold PBS, supplemented with 0.1% BSA, 1 mM MgCl₂, and 0.1 mM CaCl₂, and solubilized in RIPA buffer. Biotinylated CFTR was isolated by immunoprecipitation with M3A7 and L12B4 anti-CFTR Abs and then on Streptavidin-Sepharose (Sigma-Aldrich). Biotinylated CFTR was visualized with fluorography and its radioactivity was measured by PhosphorImage analysis.

**Subcellular Fractionation**

Cells were washed with ice-cold PBS three times, resuspended in homogenization medium (0.25 M sucrose, 10 mM Hepes, 1 mM EDTA, 1 mM DTT, pH 7.2, supplemented with 5 μg/ml leupeptin, 5 μg/ml pepstatin A, and 2 μM PMSF). CHO-BQ1, CHO-K1, CaCo-2, and T84 cells were homogenized by nitrogen cavitation as described (Zhang et al., 1998), whereas BHK cells were homogenized in a Dounce homogenizer. After the sedimentation of unbroken cells and nuclei (2,500 g, 5 min at 4°C), mitochondria were pelleted by centrifugation (10,000 g, 10 min at 4°C) from the postnuclear supernatant. Microsomes were fractionated on self-forming Percoll density gradient (25% Percoll in 0.25 M sucrose, 10 mM Hepes and 1 mM EDTA, 5 μg/ml leupeptin, 5 μg/ml pepstatin A, pH 7.3) at 25,000 g for 100 min. The density profile of the gradient was verified with density-marker beads (Sigma-Aldrich) and fractions were downloaded as described (Lukacs et al., 1997). In some experiments lysosomes were labeled with the fluid-phase marker, fluorescein-dextran (0.5 mg/ml, 70 kDa; Molecular Probes), overnight and chased in full medium for 3 h. Alkaline phosphatase, β-glucuronidase, and mannosidase II activity, specific markers of plasma membrane, lysosomes, and Golgi regions, respectively, were measured as described (Lukacs et al., 1994, 1997). The fluorescence associated with the fractions was determined with fluorescence spectrophotometry in the presence of 0.2% Triton X-100.

**Limited Proteolysis**

BHK cells expressing wt or T70 CFTR were incubated in the presence of cycloheximide (100 μg/ml) to ensure the degradation of the core-glycosylated wt and T70 CFTR (Lukacs et al., 1994). Isolation of ER-, Golgi complex-, and plasma membrane–enriched microsomes was performed as described (Zhang et al., 1998). The microsomes (0.8–1.5 mg/ml) were digested in HSE medium (10 mM Hepes, 0.25 M sucrose, pH 7.6) in the presence, at the indicated concentration, of trypsin or proteinase K for 15 min at 4°C (Zhang et al., 1998). Proteolysis was terminated by the addition of 1 mM PMSF. Samples were immediately denatured in 2× Laemmli sample buffer at 37°C for 20 min and probed by immunoblot analysis.

**Measurement of the cAMP-stimulated Iodide Conductance of the Plasma Membrane**

The plasma membrane cAMP-dependent halide conductance of BHK cells expressing T70 CFTR was determined with iodide efflux as described (Mohamed et al., 1997). Iodide efflux was initiated by replacing the load buffer with efflux medium (composed of 136 mM nitrate in place of iodide). The extracellular medium was replaced every minute with efflux buffer (1 ml). After a steady state was reached, the intracellular CAMP level was raised by agonists (10 μM forskolin, 0.2 mM cAMP, and 0.2 mM isobutyl-methyl xanthane) to achieve maximal phosphorylation of the T70 CFTR. The collection of the efflux medium resumed for an additional 6–9 min. The amount of iodide in each sample was determined with the T70 CFTR. The collection of the efflux medium resumed for an additional 6–9 min. The amount of iodide in each sample was determined with the T70 CFTR. The collection of the efflux medium resumed for an additional 6–9 min. The amount of iodide in each sample was determined with the T70 CFTR. The collection of the efflux medium resumed for an additional 6–9 min. The amount of iodide in each sample was determined with the T70 CFTR.

**Results**

**Cell Surface Delivery of the Truncated CFTR Is Preserved**

We have demonstrated previously that the steady state expression level of the complex-glycosylated CFTR missing its last 70, 82, or 98 amino acids (designated as T70, T82, and T98 CFTR) was decreased by ~90% compared with wt CFTR in heterologous expression systems (Haardt et al., 1999). In contrast, deletion of the last 26 amino acid residues (T26 CFTR) was without effect (Mickle et al., 1998; Haardt et al., 1999). It was also shown that neither the translational rate nor the biosynthetic maturation of the T70 and T82 CFTR was significantly impaired at the ER in transient COS-1 (Haardt et al., 1999) or in stable BHK expression systems (Benharouga, M., and G.L. Lukacs, unpublished data). We proposed that, in contrast to the most prevalent CF-associated processing mutations (e.g., ΔF508 CFTR), which compromise the biogenesis of CFTR, destabilization of the mature form at distal stages of the biosynthetic or endocytic pathway accounts for the phenotypic manifestation of truncated CFTR (Haardt et al., 1999).

To examine whether impaired plasma membrane targeting of the complex-glycosylated truncated CFTR can attribute to accelerated degradation, the efficacy of cell surface delivery of the mutant was determined first. BHK cells constitutively expressing wt or truncated CFTR were metabolically labeled with [³⁵S]methionine and [³⁵S]cysteine overnight and cell surface–exposed CFTR was covalently tagged with sulfo-NHS-SS-biotin. After the solubilization and immunoprecipitation of CFTR, biotinylated polypeptides were isolated on Streptavidin-Sepharose and visualized by fluorography after separation by SDS-PAGE (Fig. 1 A). PhosphorImage analysis revealed that the abundance of biotinylated T70, T82, and T98 CFTR was only 5–8% relative to wt or T26 CFTR in the mixture of clones (Fig. 1 B). The steady state level of the complex-glycosylated T70, T82, and T98 CFTR pool was also diminished to 5–10% relative to that of wt or T26 CFTR, as determined by quantitative Western blotting using L12B4 or M3A7 anti-CFTR Abs (Fig. 1 B and C). The complex and core-glycosylated forms of wt and truncated CFTR could be distinguished by their distinct electrophoretic mobility as well as their endoglycosidase H sensitivity as described previously and shown on Fig. 1, C and D (Cheng et al., 1990). The parallel decrease in the size of the complex-glycosylated and biotinylated pools of the truncated CFTR suggests that the plasma membrane targeting is largely preserved. To confirm this notion, the cell surface delivery of newly synthesized T70 CFTR was measured. Wt and T70 CFTR were pulse labeled for 15 min and those molecules that arrived at the cell surface were biotinylated during a 1-h chase. Biotinylated CFTR was affinity isolated and visualized by fluorography (Fig. 1 E, biot). Radioactivity of biotinylated forms was quantified with PhosphorImage analysis and expressed as a percentage of the respective pulse-labeled core-glycosylated CFTR (Fig. 1 E, lysate). The cell surface targeting efficiency of T70 CFTR was 74 ± 4% (mean ± SEM, n = 4) of wt CFTR. Since this measurement is compounded by the rapid degradation of the complex-glycosylated T70 CFTR (t1/2 ~ 1.5–2 h, see also Fig. 6 B; Haardt et al., 1999), the calculated targeting efficiency of the T70 CFTR represents an underestimate and suggests that the plasma membrane delivery of the complex-glycosylated T70 CFTR is largely preserved.

**Contribution of Endolysosomal Proteases to the Turnover of Complex-glycosylated Wt and Truncated CFTR**

In light of efficient clathrin-dependent internalization of CFTR (Prince et al., 1994, 1999; Lukacs et al., 1997; Bradbury, 1999) and proteolysis of other plasma membrane-resident ATP-binding cassette transporters in the vacuolar/lysosomal compartments (Loayza and Michaelis, 1998; Hicke,
brane impermeant during the labeling, indicated by the lack of biotinylated core-glycosylated forms. Complex- and core-glycosylated CFTR are indicated by black and white arrowheads, respectively. (B) The expression level of wt and truncated CFTR at the cell surface (biotinylated) and at post-ER compartments (complex glycosylated). The radioactivity of biotinylated CFTR was measured by PhosphorImage analysis in experiments as described in the legend to A. The level of the complex-glycosylated CFTR was determined by densitometry of immunoblots (C). Data represent means ± SEM (n = 3), and are expressed as the percentage of the wt, designated as 100%. (C) Expression of wt, T26, T70, T82, and T98 CFTR in BHK-21 cells. CFTR expression in cell lysate was assessed by immunoblotting using the L12B4 and M3A7 anti-CFTR Abs. BHK lane contains a lysate of the parental cells. (D) Glycosidase sensitivity of complex- and core-glycosylated wt and T70 CFTR. Cell lysates were incubated in the presence or absence of endoglycosidase H (endo H) or blotting using the L12B4 and M3A7 anti-CFTR Abs. BHK lane contains a lysate of the parental cells. (D) Glycosidase sensitivity of complex- and core-glycosylated wt and T70 CFTR. Cell lysates were incubated in the presence or absence of endoglycosidase H (endo H) or peptide-N-glycosidase F (PNGase F) for 3 h at 37°C. Polypeptides were separated by SDS-PAGE and probed by the L12B4 anti-CFTR Ab. Complex-, core-, and deglycosylated CFTR are indicated by black, white, and hatched arrowheads, respectively. (E) Targeting efficiency of newly synthesized CFTR to the cell surface. After the pulse labeling of wt or T70 CFTR for 20 min, plasma membrane insertion was visualized by fluorography. To monitor the pulse labeling of total CFTR pools, 10% of the precipitate was loaded directly (lysate). The Journal of Cell Biology, Volume 153, 2001

To test this hypothesis, the disposal rate of the metabolically labeled, complex-glycosylated T70 and T82 CFTR was measured in the presence of lysosomal protease inhibitors after allowing the conversion of the core- into complex-glycosylated form (Fig. 2 A). The degradation rate was unaltered upon exposing the cells to NH$_4$Cl, chloroquin, or bafilomycin B, agents that inhibit endolysosomal proteolysis by dissipating the acidic luminal pH and interfering with cargo delivery (Fig. 2 B). Similarly, leupeptin and pepstatin A, inhibitors of cathepsins B, H, L, N, S, and T (Seglen, 1983), have a negligible effect on the degradation rate (Fig. 2 A and B) and the steady state expression of truncated CFTRs (Fig. 2 C). In contrast, these drugs stabilized the interleukin 2 receptor α chain (Tac), which is targeted for lysosomal degradation (Fig. 2 D; Hemar et al., 1995), validating their efficacy and suggesting that the initial proteolysis of the truncated CFTR is largely independent of endolysosomal proteases.

Pulse-chase analysis has revealed that the disposal of the complex-glycosylated wt CFTR was mitigated by NH$_4$Cl and chloroquin (Fig. 2, E and F). To further examine the discordant role of lysosomal proteases in the wt and T70 CFTR degradation, subcellular fractionation was performed, after the enrichment of short-lived proteolytic intermediates that may have been difficult to detect by treating the cells with the cathepsin inhibitors. Heavy and light microsomes, containing predominantly lysosomes and Golgi complex plasma membrane, and endosomes, respectively, were isolated on Percoll density gradient (Fig. 3 A).

Although cathepsin inhibitors stabilized the complex-glycosylated wt CFTR by 7–10-fold in lysosomes as well as in the light-density fraction, only a modest accumulation of T70 CFTR could be documented by immunoblot analysis (Fig. 3 B). Similar results were obtained in lysosomes isolated by the calcium-precipitation method (data not shown; Kawashima et al., 1998). Surprisingly, leupeptin and pepstatin A provoked the accumulation of degradation intermediates of both wt and T70 CFTR predominantly in lysosomes (Fig. 3 B). These inhibitors also provoked the appearance of breakdown products in isolated lysosomes of intestinal epithelia (CaCo-2 and T84) expressing CFTR endogenously, implying that lysosomal proteolysis cannot be attributed to heterologous overexpression (data not
peptatin A (50 µg/ml). Metabolically labeled cells were chased for the indicated time, and Tac was isolated by immunoprecipitation and visualized by fluorography. (E and F) Metabolic stability of the complex-glycosylated wt CFTR was determined in stably transfected CHO cells in the presence of NH4Cl (15 mM), chloroquin (200 µM), or leupeptin plus pepstatin A (leu+pep; 50 µg/ml) as described for A and B. Statistical analysis was performed on samples subjected to a 20-h chase (F). Data are means ± SEM, n = 3.

Figure 2. The role of lysosomal proteases in the metabolism of truncated and wt CFTR. (A) After the pulse labeling of T70, T82, and T98 CFTR expressors, BHK cells were chased for 2 h to ensure the conversion of core-glycosylated form to complex-glycosylated CFTR at 37°C. Subsequent chase was performed in the presence of NH4Cl (15 mM), Bafilomycin B (Baf B; 2 µM), and leupeptin plus pepstatin A (leu+pep; 50 µg/ml) were present during the entire pulse–chase. CFTR was immunoprecipitated and visualized by fluorography. (B) The radioactivity remaining in the complex-glycosylated T70, T82, and T98 CFTR after the chase was quantified by PhosphorImage analysis in experiments shown in A and expressed as the percentage of the initial amount present after 2 h of chase. Data represent means ± SEM, n = 3. (C) The effect of chatepsin inhibitors on the expression level of truncated CFTR. BHK transfectants were incubated with or without leupeptin and pepstatin A (50 µg/ml) for 4 h. Equal amounts of protein were probed by immunoblotting as described in the legend to Fig. 1 C. (D) The metabolic stability of Tac in BHK cells. The turnover of Tac was determined in the presence or absence of leupeptin and proteins after their ligand-induced internalization (Hochstrasser, 1996; Bonifacino and Weissmann, 1998; Hershko and Ciechanover, 1995; Brodsky and McCracken, 1999; Plemper and Wolf, 1999; Schwartz and Dierichs, 1999). To reveal the involvement of the 26S proteasome in the metabolism of the truncated CFTR, the impact of the proteolytic intermediates derived from both T70 and wt CFTR.

Proteasome-dependent Degradation of the Complex-glycosylated Truncated CFTR

The 26S proteasome is responsible for the degradation of misfolded polypeptides recognized by the ER quality control, short-lived cytosolic, and some plasma membrane proteins after their ligand-induced internalization (Hochstrasser, 1996; Bonifacino and Weissmann, 1998; Hershko and Ciechanover, 1995; Brodsky and McCracken, 1999; Plemper and Wolf, 1999; Schwartz and Dierichs, 1999). To reveal the involvement of the 26S proteasome in the metabolism of the truncated CFTR, the impact of the proteolytic intermediates derived from both T70 and wt CFTR.

shown). Considering that cathepsin inhibitors are unable to promote the ER processing of the core-glycosylated form (Lukacs et al., 1994; Ward and Kopito, 1994), our results suggest that endolysosomal proteases are essential for the elimination of the complex-glycosylated full-length wt CFTR. In addition, endolysosomal proteases appear to be involved in the processing of the proteolytic intermediates derived from both T70 and wt CFTR.

Proteasome-dependent Degradation of the Complex-glycosylated Truncated CFTR

The 26S proteasome is responsible for the degradation of misfolded polypeptides recognized by the ER quality control, short-lived cytosolic, and some plasma membrane proteins after their ligand-induced internalization (Hochstrasser, 1996; Bonifacino and Weissmann, 1998; Hershko and Ciechanover, 1995; Brodsky and McCracken, 1999; Plemper and Wolf, 1999; Schwartz and Dierichs, 1999). To reveal the involvement of the 26S proteasome in the metabolism of the truncated CFTR, the impact of the peptide aldehyde, MG 132 (CBZ-leu-leu-leucinal), and lactacystin, a specific, irreversible inhibitor of the 20S subunit, was assessed (Fenteany et al., 1995).

The disappearance of the complex-glycosylated, but not the core-glycosylated, T70, T82, and T98 CFTR was inhibited 2.3-, 2.6-, and 2.1-fold, respectively, by lactacystin when the drug was present during the pulse labeling and chase (Figs. 4, A and B, and 5 A). MG132 exerted a less pronounced effect (Fig. 4 B). Comparable inhibition was
lysosomes in the high density fractions was confirmed by the accumulation of fluorescein-dextran (70 kD, 1.5 mg/ml) as well after an overnight labeling and a 3-h chase. (B) BHK cells expressing wt or T70 CFTR were treated with leupeptin and pepstatin A overnight comprising the majority of lysosomes and plasma membrane, Golgi regions, and endosomes, respectively, were pooled. Equal amounts (50 μg) of protein were loaded and probed with NBD1 (L12B4) and NBD2 (M3A7) specific anti-CFTR Abs using ECL.

To rule out that cross talks between lysosomal and proteasomal degradation pathway account for the stabilization of the complex-glycosylated T70 CFTR, the specificity of the drugs was examined on BHK cells expressing Tac-TCRα or Tac-Lamp1 chimeras. Although the former polypeptide is a substrate of the ERAD (Bonifacino et al., 1990), the latter is targeted for lysosomal proteolysis (Marks et al., 1996). As we anticipated, proteasome inhibitors mitigated the disappearance of Tac-TCRα, but not Tac-Lamp1, whereas bafilomycin B, but not the proteasome inhibitors, stabilized Tac-Lamp1 (Fig. 5, B and C). Consistent with the notion that proteasome activity accounts, at least in part, for the proteolysis of the complex-glycosylated truncated CFTR, proteasome inhibitors increased the steady state level of the complex-glycosylated T70, T82, and T98 CFTR by two- to fourfold according to densitometric analysis of immunoblots (Fig. 5 D). This was also reflected by the elevated cAMP-activated anion conductance of the plasma membrane (Fig. 5 E). Lactacystin treatment significantly increased the protein kinase A-stimulated iodide release from BHK cells constitutively expressing T70 CFTR as compared with nontreated cells (Fig. 5 E).

**Proteasome-dependent Turnover of Cell Surface Resident T70 CFTR**

To investigate the influence of proteasome inhibitors on the residence time of truncated CFTR at the cell surface, the turnover of biotinylated T70 CFTR was measured by the pulse–chase technique. The half-life of biotinylated T70 CFTR is sevenfold shorter (t1/2 ~ 1.9 h) than the wt CFTR (t1/2 ~ 14.5 h; Fig. 6, A and B). Lactacystin and MG132 inhibited the turnover of biotinylated T70 CFTR by 2.6- and 1.9-fold, respectively. This observation provides direct support for our hypothesis that proteasomes,
directly or indirectly, are involved in the proteolysis of complex-glycosylated T70 CFTR from the cell surface and endosomal compartments (Fig. 6, C and D).

**Ubiquitination of the Complex-glycosylated T70 CFTR**

Since recognition of most of the substrates destined for destruction by the proteasome requires polyubiquitin modification (Hershko and Ciechanover, 1998; Laney and Hochstrasser, 1999; Plemper and Wolf, 1999; Hirsh and Ploegh, 2000), we examined whether T70 CFTR is subject to ubiquitin attachments. COS-1 cells were transiently cotransfected with plasmids encoding for the wt or T70 CFTR and HA-tagged ubiquitin (HA-Ub). HA-Ub was detected with the monoclonal anti-HA Ab in immunoprecipitated and fluorography. The radioactivity remaining in the complex-glycosylated CFTR was measured by PhosphorImage analysis and expressed as the percentage of the amount after a 2-h chase (B). Data are means + SEM, n = 3–4. (C and D) To rule out that lactacystin (10 μM) delays the degradation of the complex-glycosylated form by promoting the biosynthesis or the conversion of the core-glycosylated form, cells were treated with lactacystin after the pulse labeling (C) or after the conversion of the core- to complex-glycosylated T70 (D). This protocol provided similar inhibition of the complex-glycosylated turnover as reported for A. When indicated, BFA (5 μg/ml) was included to prevent the conversion of the residual core-glycosylated form (D and E). (E–G) Comparison of the turnover rate of folded wt and T70 CFTR in the ER and post-Golgi compartments. After the pulse labeling of BHK transfectants, the fully mature core-glycosylated T70 and wt CFTR were accumulated in the ER by BFA (5 μg/ml) during a 2-h chase. The disappearance of the folded core-glycosylated form was monitored during a subsequent 15-h chase in the presence of BFA and was expressed as the percentage of the amount detected after a 2-h chase (F and G). The stability of the complex-glycosylated T70 and wt CFTR, representing post-Golgi pools, was determined as described for A.
T70 CFTR (Fig. 7 A, top, lanes 8–10). Similar results were obtained by monitoring the conjugation of endogenous Ub with a monoclonal anti-Ub Ab (Fig. 7 A, middle, lanes 6–10). Ubiquitinated T70 CFTR could not be detected in cells expressing T70 CFTR or HA-Ub individually (Fig. 7 A, lanes 1–3), validating the specificity of the assay. To discriminate whether polyubiquitinated T70 CFTR was derived from the core- and/or the complex-glycosylated T70 CFTR (Jensen et al., 1995; Ward et al., 1995; Xiong et al., 1999), double immunoprecipitation of metabolically labeled T70 CFTR was performed.

Stably transfected BHK cells were pulse labeled for 20 min and chased for 2 h to ensure the elimination of core-glycosylated T70 CFTR, verified by fluorography (Fig. 7 B, bottom, lanes 1 and 2; see also Fig. 4 D). In a second set of samples, separation of ubiquitinated adducts was achieved by sequential immunoprecipitation with anti-CFTR and then with anti-Ub Ab. The results show that a negligible amount of polyubiquitinated and core-glycosylated T70 CFTR persisted after the initial 2-h chase (Fig. 7 B, top and bottom, lanes 1 and 2). In contrast, radioactivity appeared in the high molecular weight, polyubiquitinated T70 CFTR when MG132 was present during the last 2 h of chase (Fig. 7 B, top, lane 4). Accumulation of polyubiquitinated T70 CFTR was more pronounced in COS-1 cells transiently coexpressing T70 CFTR and HA-Ub (Fig. 7 C). This is most likely due to the higher immunoprecipitation efficiency of the anti-HA Ab. Ubiquitinated conjugates were not detectable upon inhibition of lysosomal proteolysis, or in mock transfected cells (Fig. 7 B, top and middle, and C). Considering that the turnover of the complex-glycosylated, but not the core-glycosylated T70 CFTR, is sensitive to proteasome inhibitors and the core-
glycosylated form has been largely eliminated before proteasome inhibition, we conclude that at least a fraction of polyubiquitinated T70 CFTR originates from the complex-glycosylated T70 CFTR. Although we cannot rule out that a small amount of polyubiquitinated T70 CFTR is derived from the core-glycosylated form, the following observations substantiate the notion that the complex-glycosylated T70 CFTR can form ubiquitinated adducts. Ubiquitinated complex-glycosylated form was visualized by anti-Ub Abs after the separation of the core- and complex-glycosylated forms by immunoprecipitation with anti-CFTR Abs and wheat germ agglutinin affinity chromatography (data not shown). Furthermore, coexpression of the dominant negative K48RUb with T70 CFTR delayed the disposal of the complex-glycosylated mutant CFTR (data not shown).

Deletion of the COOH-terminal Tail Structurally Destabilizes CFTR

Nonnative or partially denatured soluble proteins are subjected to ubiquitination and/or proteasome-mediated degradation (Pacifici et al., 1993; Sadis et al., 1995; Michalek et al., 1996; Gilon et al., 1998; Laney and Hochstrasser, 1999). A similar scenario may prevail for T70 CFTR if the COOH-terminal tail is engaged in the structural stabilization of CFTR in the post-ER compartment. A large body of evidence demonstrates the existence of intra- and intermolecular interactions in CFTR (Seibert et al., 1996; Ostedgaard et al., 1997, 2000; Hall et al., 1998; Neville et al., 1998; Zhang et al., 1998; Naren et al., 1999; Lu and Pedersen, 2000).

To compare the conformational stability of the complex-glycosylated wt and T70 CFTR, in situ protease susceptibility and in vivo thermostability assays were performed. The conformation of the cytosolic domains was probed with limited proteolytic digestion in conjunction with immunoblotting, a method we have implemented to reveal conformational difference between the wt and the ΔF508 CFTR (Zhang et al., 1998). Intact microsomes were isolated by differential centrifugation from BHK cells, enriched in the complex-glycosylated wt or T70 CFTR by cyclohexamide chase, and subjected to limited proteolysis in the presence of an increasing concentration of trypsin. Immunoblot analysis of the proteolytic fragments with the L12B4 anti-CFTR Ab recognizing the NBD1 demonstrates a distinct proteolytic digestion pattern and a moderate, but reproducibly increased protease sensitivity of the complex-glycosylated T70 CFTR compared with wt CFTR (Fig. 8). Similar results were obtained with proteinase K and using the NBD2-specific, M3A7 anti-CFTR Ab (data not shown), indicating that not only the NBD2, but also the NBD1 conformation was altered upon truncating the COOH terminus.

If the complex-glycosylated T70 CFTR was conformationally unstable, it was anticipated that the polypeptide in vivo thermostability would be compromised. The temperature dependence of the turnover of the complex-glycosylated wt and T70 CFTR was compared by metabolic pulse–chase studies. The turnover of the complex-glycosylated T70 CFTR was more than fivefold faster at 40°C ($t_{1/2} \sim 0.5$ h) than at 37°C ($t_{1/2} \sim 2.7$ h) (Fig. 9, A and C). In sharp contrast, the turnover of the wt CFTR was only marginally affected at 40°C ($t_{1/2} \sim 10.5$ vs. 15 h at 37°C) (Fig. 9, A and C).
B and D). The simplest interpretation of these data is that the intrinsic structural instability of the T70 CFTR becomes more apparent at elevated temperature, leading to thermodenaturation and proteolysis, whereas the compact tertiary structures of wt CFTR are resistant to unfolding.

**Discussion**

A combination of transcriptional, cotranslational, and posttranslational mechanisms contributes to the ER quality control, preventing misfolded secretory and membrane proteins from traversing the secretory pathway (Ellgaard et al., 1999; Wickner et al., 1999; Mori, 2000). Nevertheless, several examples demonstrate that the fidelity of the ER quality control is far from perfect. Nonfunctional polypeptides can escape ER retention, whereas mutants with partially or fully preserved biological function are being trapped, causing severe human diseases such as CF and alpha 1–protease inhibitor deficiency (Thomas et al., 1995; Zielenski and Tsui, 1995; Aridor and Balch, 1999; Schwartz and Ciechanover, 1999). Nonnative polypeptides could also be generated in post-ER compartments as a result of unfolding upon environmental stresses or mutations that compromise the native form stability (Goldenberg, 1992; Pacifici et al., 1993; Parsell and Lindquist, 1993; Sitte et al., 1998). Little is known about the mechanism responsible for the degradation of abnormal membrane proteins from post-ER compartments.

In mammalian cells, aggregated furin, incompletely assembled Golgi coronavirus E1, and mutant connexin32 are destined for lysosomal degradation from the Golgi region without reaching the cell surface (Armstrong et al., 1990; Wolins et al., 1997; VanSlyke et al., 2000). A post-ER quality control mechanism appears to be responsible for targeting and vacuolar degradation of mutant plasma membrane ATPase, the late Golgi protease Kex2, and a
model protein, comprising the secretory invertase and the \( \text{NH}_2 \) terminus of the lambda repressor in *Saccharomyces cerevisiae* (Wilcox et al., 1992; Chang and Fink, 1995; Hong et al., 1996). Aggregation of unoccupied class II major histocompatibility complex molecules and cross-linking of cell surface membrane proteins, such as the transferrin receptor, can evoke preferential lysosomal targeting and degradation (Weissman et al., 1986; Amigorena et al., 1995). Although most of these examples illustrate that nonnative membrane protein is targeted for lysosomal proteolysis either before their arrival to the cell surface or after their internalization, the complex-glycosylated truncated CFTR has a distinct intracellular fate.

We presented compelling evidence indicating that the dramatically decreased expression level and residence time of the complex-glycosylated truncated CFTR cannot be attributed to missorting for lysosomal degradation at the trans-Golgi or endosomal compartment. Instead, the truncated CFTR is targeted to the plasma membrane with comparable efficiency to its wt counterpart (Fig. 1). The turnover of the total and cell surface biotinylated T70 CFTR pools was insensitive to inhibitors of endolysosomal proteases. In contrast, weak bases and cathepsin inhibitors stabilized the full-length form and degradation intermediates of wt CFTR in transfectants as well as in epithelia, highlighting the multiple role of endolysosomal proteolysis in the turnover of wt CFTR (Figs. 2 and 3).

Several criteria were used to establish that proteasomes are involved in the accelerated metabolism of the truncated CFTR from post-Golgi compartments, including the cell surface. First, the degradation rates of the complex-glycosylated T70, 82, and 98 CFTR were delayed in the presence of lactacystin, the most specific inhibitor of proteasome (Fenteany et al., 1995; Fig. 4). Second, a dramatic extension of the plasma membrane residence time of biotinylated T70 CFTR was evoked by lactacystin (Fig. 6), implying that proteasomes are indispensable in the proteolysis of the truncated CFTR from the cell surface and/or endosomal compartment. Since proteasome inhibitors had no impact on the degradation of Tac-Lamp1, an indirect effect of lactacystin on lysosomal proteolysis could be precluded (Fig. 5). Third, MG132 and lactacystin evoked the accumulation of polyubiquitinated adducts of the complex-glycosylated T70 CFTR, consistent with the notion that a fraction of the T70 CFTR is tagged by polyubiquitin chain(s) before degradation (Fig. 7). Finally, both MG132 and lactacystin partially restored the expression level of complex-glycosylated T70, T82, and T98 CFTR, as well as the plasma membrane cAMP-activated chloride conductance of T70 CFTR transfectants without facilitating the biogenesis of the mutants (Fig. 5, D and E). Although these observations indicate that proteasome activity is one of the rate-limiting steps for the turnover of the full-length complex-glycosylated T70 CFTR, proteasome inhibitors failed to restore the mutant stability to that of the wt CFTR.
CFTR. This could be explained by incomplete inhibition of proteasome activity and/or the involvement of other, presently unidentified proteolytic mechanisms.

The COOH-terminal tail of CFTR might confer stability to the mature CFTR by several mechanisms or a combination thereof. Deletion of the COOH terminus, comprising a postsynaptic density-95, disc-large, and zonula occludens-1–binding motif (476DTLR) that ensures the association of CFTR with EBP-50 (for ezrin–radixin–moesin–binding phosphoprotein 50) both in vitro and in vivo may facilitate lysosomal degradation by compromising endosomal sorting for recycling (Hall et al., 1998; Short et al., 1998; Moyer et al., 2000). A similar paradigm was proposed for the accelerated degradation of the β2-adrenergic receptor upon preventing its binding to EBP-50 (Cao et al., 1999). However, this possibility appears to be unlikely, since the steady state expression level and turnover rate of a CFTR variant lacking the COOH-terminal 26 amino acid residues are normal (Mickle et al., 1998; Haardt et al., 1999). Neither can aggregation of T70 CFTR at the trans-Golgi or at early endosomes target the mutant for lysosomal degradation. Finally, the absence of the COOH-terminal tail may structurally destabilize the folded CFTR, increasing the portion of nonnative molecules that are susceptible to proteolysis.

Evidence suggests that nonnative states of soluble polypeptides induced by mutations or thermal or chemical denaturation can lead to accelerated degradation (Parsell and Lindquist, 1993; Herskko and Ciechanover, 1998; Brodsky and McCracken, 1999; Plemer and Wolf, 1999), a paradigm that may apply to the degradation of nonnative plasma membrane proteins, including the truncated CFTR, as well. Based on the enhanced protease susceptibility and the decreased in vivo thermostability of T70 CFTR (Figs. 8 and 9), we speculate that structural destabilization of the native form is induced by disrupting interaction(s) of the COOH terminus. Using various yeast screening assays and site-directed mutagenesis of the Deg-1 proteolytic motif in the MATa2 transcription factor, it has been established that ubiquitin-conjugating enzymes (Ubc6 and Ubc7) can recognize hydrophobic stretches and exposed hydrophobic surfaces on amphipathic helices (Sadis et al., 1995; Gilon et al., 1998; Johnson et al., 1998). These or similar motifs, normally buried inside the globular domains of CFTR or inserted into the membrane plane, may serve as recognition signal(s). In support of this notion, the decreased plasma membrane residence time and impaired expression level of the β2- and the α2β2-adrenergic receptors were also attributed to structural destabilization (Gether et al., 1997; Wilson and Limbird, 2000). However, the mechanism responsible for the downregulation of these G protein–coupled receptors, which could be partially rescued with ligand stabilization, has remained obscure.

A key question that remains to be resolved is whether ubiquitination is a prerequisite for proteasome-dependent degradation of the mutant CFTR from the cell surface or endosomal compartment. Several tyrosine kinase and G protein–coupled receptors have been observed to undergo ligand-induced ubiquitination and downregulation via lysosomal and/or proteasomal degradation (Bonifacino and Weisman, 1998; Herskho and Ciechanover, 1998; Hicke, 1999; Strous and Govers, 1999). Ubiquitination also appears to be necessary and sufficient to induce the internalization and downregulation of plasma membrane receptors and transporters (e.g., FUR4, GAP1, STE2, STE3, and STE6) via vacuolar proteolysis in yeast (Hicke, 1999). The constitutive downregulation of the epithelial sodium channel (ENaC), in association with the Nedd4 ubiquitin-ligase, was proposed to follow a similar degradation route, in contrast to the unassembled subunits of the channel, which were degraded by a proteasome-dependent mechanism at the ER (Staub et al., 1997).

Since both covalent and noncovalent attachment of ubiquitins can serve as a degradation signal of plasma membrane proteins via internalization (Govers et al., 1999; Shih et al., 2000), one possible scenario is that augmented ubiquitination of CFTR, or an associated protein, facilitates the internalization of the mutant. On the other hand, in light of multiple tyrosine- and dileucine-based endocytic signals in CFTR, ubiquitin attachment may not be a prerequisite for endocytosis (Lukaes et al., 1997; Prince et al., 1999; Hu et al., 2001). Consistent with the dispensable nature of ubiquitination, downregulation of the β2-adrenergic and mutant m2-muscarinic receptors can proceed without endocytosis, presumably by direct association with proteasome and/or other, presently unidentified proteases (Jockers et al., 1999; Wilson and Limbird, 2000). The recognition that both 26S proteasome and P700 subunit are able to degrade nonnative polypeptides lacking polyubiquitin conjugates supports the notion that a ubiquitin-independent degradation mechanism cannot be ruled out (Murakami, 1992; Braun et al., 1999; Sheaff et al., 2000; Strickland et al., 2000). Importantly, these degradation pathways are not mutually exclusive and may function in parallel.

Since the retrograde translocation of the T70 CFTR via the translocon is unlikely to occur in post-Golgi compartments (Xiong et al., 1999), the coordinated action of multiple proteolytic systems is invoked to resolve the topological problem of disposing transmembrane segments and exofacial loops of the T70 CFTR. Degradation appears to be initiated by the unfolding of cytosolic domains in a proteasome-dependent manner. The biochemical as well as functional rescue of cell surface resident T70, but not wt CFTR (data not shown), by proteasome inhibitors substantiates this hypothesis. Whereas the initial cleavage of the mature wt CFTR, as opposed to mutant, relies on the activity of lysosomal proteases, subsequent degradation of wt and T70 CFTR converges in endolysosomes, demonstrated by their overlapping proteolytic fragmentation pattern in the presence of cathepsin inhibitors (Fig. 3 B).

Although the truncated CFTR is one of the first mutant plasma membrane proteins subjected to sequential proteosomal and lysosomal breakdown, the coordinated action of these proteolytic systems is not without precedent. Although both lysosomes and proteasomes are involved in the constitutive and ligand-induced disposal of connexin43, the renal Na+/P− cotransporter, and the PDGF β receptor, respectively (Mori et al., 1995; Laiing et al., 1997; Pfister et al., 1998), the recognition mechanism of these substrates by the proteasome remains unknown. Considering that deletion of the COOH-terminal tail appears to destabilize CFTR structurally, we propose that the ubiquitin–proteasome pathway may play a role in the recognition
elimination of not only the T70 CFTR, but also other nonnative or partially unfolded plasma membrane proteins.

We thank R. Haguenaou-Tsapis (Jacques Monod, University of Paris VII, Paris, France), J. Bonifacino (National Institutes of Health, Bethesda, MD), and M. Fukuda (The Burnham Institute, La Jolla, CA) for their generous gifts of cDNA. The authors are indebted to J. Brodsky and A. Weissman for helpful suggestions and J. Szapor for critical reading of the manuscript.

This work was supported by the Medical Research Council of Canada, the Canadian Cystic Fibrosis Foundation, and the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Instrumentation was covered in part by a block term grant from the Ontario Thoracic Society. M. Benharouga was supported by a Canadian Health, National Institute of Diabetes and Digestive and Kidney Diseases, the Canadian Cystic Fibrosis Foundation, and the National Institutes of Health, Bethesda, MD, and M. Fukuda (The Burnham Institute, La Jolla, CA) for their generous gifts of cDNA. The authors are indebted to J. Brodsky and A. Weissman for helpful suggestions and J. Szapor for critical reading of the manuscript.

Submitted: 3 November 2000
Revised: 30 March 2001
Accepted: 30 March 2001

References

Amigorena, S., P. Webster, J. Drake, J. Newcomb, P. Cresswell, and I. Mellman. 1995. Invariant chain cleavage and peptide loading in major histocompatibility complex class II vesicles. J. Exp. Med. 181:1729–1741.

Aridor, M., and W.E. Balch. 1999. Integration of endoplasmic reticulum signal peptides in health and disease. Nat. Med. 5:745–751.

Armstrong, J., S. Patel, and P. Riddle. 1990. Lysosomal sorting mutants of coronavirus E1 protein, a Golgi membrane protein. J. Cell Sci. 95:191–197.

Baumeister, W., J. Walz, F. Zuhu, and E. Scemuller. 1998. The proteasome: paradigm of a self-compartmentalizing protease. Cell 92:367–380.

Bonifacino, J.S., and A.M. Weismann. 1998. Ubiquitin and the control of protein fate in the secretory and endocytic pathway. Ann. Rev. Cell Dev. Biol. 14:19–57.

Bonifacino, J.S., C.K. Suzuki, and R.D. Klausner. 1990. A peptide sequence confers retention and rapid degradation in the endoplasmic reticulum. Science. 247:79–82.

Bradbury, N.A. 1999. Intracellular CFTR: localization and function. Physiol. Rev. 79:S15–S192.

Braun, B.C., M. Glickman, R. Kraft, B. Dahlmann, P.-M. Kloetzel, D. Finley, and M. Schmidt. 1999. The base of the proteasome regulatory particle exhibits its chaperone-like activity. Nat. Cell Biol. 2:221–226.

Brodsky, J.L., and A.A. McCracken. 1999. ER-associated and proteasome-mediated protein degradation: how two topologically restricted events came together. Trends Cell Biol. 7:151–156.

Brodsky, J.L., and A.A. McCracken. 1999. ER protein quality control and proteasome-mediated protein degradation. Cell Dev. Biol. 10:507–513.

Cao, T.T., H.W. Deacon, D. Reczek, A. Bretsch, and M. von Zastrow. 1999. A kinase-regulated PDZ-domain interaction controls endocytic sorting of the β2-adrenergic receptor. Nature. 401:286–289.

Chang, A., and G.R. Fink. 1995. Targeting of the yeast plasma membrane H+/H1001 exchanger regulatory protein determines binding to the Na+/H+ exchanger regulatory family of PDZ proteins. Proc. Natl. Acad. Sci. USA. 92:8496–8501.

Henrich, A., A. Subtil, M. Lieb, E. Morelon, R. Helfo, and A. Dautry-Varsat. 1995. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor α, β, and γ chains. J. Cell Biol. 129:55–64.

Hershko, A., and A. Ciechanover. 1998. The ubiquitin system. Annu. Rev. Biochem. 67:425–479.

Hicke, L. 1999. Gettin’ down with ubiquitin: turning off cell-surface receptors, transporters and channels. Trends Cell Biol. 9:107–112.

Hirsh, C., and H.L. Ploegh. 2000. Intracellular targeting of the proteasome. Trends Cell Biol. 10:268–272.

Hochstrasser, M. 1996. Ubiquitin-dependent protein degradation. Annu. Rev. Genet. 30:405–439.

Hong, E., A.R. Davidson, and C.A. Kaiser. 1996. A pathway for targeting solubilized proteins to the yeast vacuole. J. Cell Biol. 135:623–633.

Hu, W., M. Howard, and G. Lukacs. 2001. Multiple endocytic signals in the C-terminal tail of the CFTR. Biochem. J. 354:561–572.

Hurle, S.M., and A. Helnius. 1989. Protein oligomerization in the endoplasmic reticulum. Annu. Rev. Cell Biol. 5:1–23.

Jensen, T.J., M.A. Loo, S. Pind, D.B. Williams, A.L. Goldberg, and J.R. Riordan. 1995. Multiple proteolytic systems including the proteasome, contribute to CFTR processing. Cell. 83:129–135.

Jockers, R., S. Angers, A.D. Silva, P. Benaroch, A.D. Stroberg, M. Bouvier, and S. Marullo. 1999. β-arrestin-dependent receptor down-regulation. Evidence for a pathway that does not require endocytosis. J. Biol. Chem. 274:28900–28908.

Johnson, P.R., R. Swanson, L. Rakhilina, and M. Hochstrasser. 1998. Degradation signal masking by heterodimerization of MAT2e and MATA1 blocks their mutual destruction by the ubiquitin-proteasome pathway. Cell. 94:217–227.

Kartner, N., O. Augustin, T.J. Jensen, A.L. Naismith, and J.R. Riordan. 1992. Mislocalization of DF508 CFTR in cystic fibrosis sweat gland. Nat. Genet. 1:327–327.

Katzmann, D.J., E.A. Epping, and W.S. Moyer-Rowley. 1999. Mutational disruption of plasma membrane trafficking of Saccharomyces cerevisiae Yor1p, a homologue of mammalian multidrug resistance protein. Mol. Cell. Biol. 19: 9898–9909.

Kawashima, A., S. Sato, M. Kawashima, K. Nitta, W. Yumura, N. Sugino, H. Nihei, and Y. Natori. 1998. A simple procedure for the isolation of rat kidney lysosomes. Kidney Int. 54:275–278.

Kopito, R.R. 1999. Biosynthesis and degradation of CFTR. Rev. Physiol. 79: S167–S173.

Laing, J.G., P.N. Tadros, E.M. Westphale, and E.C. Beyer. 1997. Degradation of connexin43 gap junctions involves both the proteasome and the lysosome. Exp. Cell Res. 236:482–492.

Laney, D.J., and M. Hochstrasser. 1999. Substrate targeting in the ubiquitin system. Cell. 97:427–430.

Loayza, S., and D. Michaelis. 1998. Role for the ubiquitin-proteasome system in the vacuolar degradation of Ste5p, a factor transporter in Saccharomyces cerevisiae. Mol. Cell. Biol. 18:779–789.

Loo, M.A., T.J. Jensen, L. Cui, Y.-X. Hou, X.-B. Chang, and J.R. Riordan. 1998. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. EMBO J. 17: 6879–6887.

Lu, N.T., and P.L. Pedersen. 2000. CFTR: the purified NBF1 protein. Arch. Biochem. Biophys. 375:7–20.

Lukacs, G.L., X.B. Chang, C. Bear, N. Kartner, A. Mohamed, J.R. Riordan, and S. Grinstein. 1993. The DF508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. J. Biol. Chem. 268:25192–25198.

Lukacs, G.L., A. Mohamed, N. Kartner, X.B. Chang, J.R. Riordan, and S. Grinstein. 1994. Conformational maturation of CFTR but not its mutant counterpart (DF508) occurs in the ER and requires ATP. EMBO J. 13: 6076–6086.

Lukacs, G.L., G. Segal, N. Kartner, S. Grinstein, and F. Zhang. 1997. Constitutive internalization of cystic fibrosis transmembrane conductance regulator occurs via clathrin-dependent and -independent routes and is regulated by a protein phosphorylation. Biochim. Biophys. Acta. 1323:353–361.

Marks, M.S., L. Woodruff, H. Ohno, and J.S. Bonifacino. 1996. Protein targeting by tyrosine- and dileucine-based signals: evidence for distinct saturable components. J. Cell Biol. 135:341–354.

Meacham, G.C., Z. Lu, S. King, E. Sorscher, A. Tousson, and D.M. Cyr. 1999. The Hdg-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. J. Biol. Chem. 274:18492–18497.
brosis transmembrane conductance regulator gene associated with elevated sweat chloride concentration in the absence of cystic fibrosis. *Hum. Mol. Genet.* 7:729–735.

Mohamed, A., D. Ferguson, F.S. Seibert, H.M. Cai, N. Kartner, S. Grinstein, J.R. Riordan, and G.L. Lukacs. 1997. Functional expression and apical localization of the cystic fibrosis transmembrane conductance regulator in MDCK I cells. *Biochem. J.* 322:259–265.

Mori, A., K. Tanaka, S. Omura, and Y. Saito. 1995. Degradation process of ligand-stimulated platelet-derived growth factor β-receptor involves ubiquitin-proteasome proteolytic pathway. *J. Biol. Chem.* 270:29447–29452.

Mori, K. 2000. Tripartite management of unfolded proteins in the endoplasmic reticulum. *Cell.* 101:451–454.

Moyer, B.D., M. Duhaime, C. Shaw, J. Denton, D. Reynolds, K.H. Karlson, J.L. Clarke, and D.M. Clarke. 1996. Cytoplasmic loop three of cystic fibrosis transmembrane conductance regulator contributes to the regulation of chloride channel activity. *J. Biol. Chem.* 271:15139–15145.

Sheaff, R.J., J.D. Singer, J. Swanger, M. Smitherman, J.M. Roberts, and B.E. Clurman. 2000. Proteasomal turnover of p21V13 does not require p21V13 ubiquitination. *Mol. Cell.* 5:403–410.

Shih, S.C., K.E. Slop-Moud and L. Hicke. 2000. Monoubiquitin carries a novel internalization signal that is appended to activated receptors. *EMBO J.* 19:187–196.

Short, D.B., K.W. Trotter, D. Rezcek, S.M. Kreda, A. Bretsch, R.C. Boucher, M.J. Stutts, and L. Milgram. 1998. An apical PDZ protein anchors the CFTR to the cytoskeleton. *J. Biol. Chem.* 273:19797–19801.

Sitte, N., K. Merker, and T. Grune. 1998. Proteasome-dependent degradation of oxidized proteins in MRC-5 fibroblasts. *FEBS Lett.* 440:399–402.

Staub, O., I. Gautschi, T. Ishikawa, K. Breitschopf, A. Ceccanelli, L. Schild, and D. Rotin. 1997. Regulation of stability and function of the epithelial Na-channel (ENaC) by ubiquitination. *EMBO J.* 16:6325–6336.

Strickland, E., H. Hakala, P.J. Thomas, and G.N. DeMartin. 2000. Recognition of misfolding proteins by PA700, the regulatory subcomplex of the 26 S proteasome. *J. Biol. Chem.* 275:5565–5572.

Strous, G.J., and R. Govers. 1999. The ubiquitin-proteasome system and endocytosis. *J. Cell Sci.* 112:1417–1423.

Thomas, P.J., B.-H. Qu, and P.L. Pedersen. 1995. Defective protein folding as a basis of human disease. *Trends Biochem. Sci.* 20:456–459.

Van Oene, M.G., L. Lukacs, and J.M. Rommens. 2000. Cystic fibrosis mutations lead to carboxyl-terminal fragments that highlight an early biogenesis step of the CFTR. *J. Biol. Chem.* 275:19577–19584.

VanSlyke, J.K., S.M. Deschenes, and L.S. Musul. 2000. Intracellular transport, assembly, and degradation of wild-type and disease-linked mutant gap junction proteins. *Mol. Biol. Cell.* 11:1933–1946.

Ward, C.L., and R.R. Kopito. 1994. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. *J. Biol. Chem.* 269:25710–25718.

Ward, C.L., S. Omura, and R.R. Kopito. 1995. Degradation of CFTR by the ubiquitin-proteasome pathway. *Cell.* 83:121–127.

Weissman, A.M., R.D. Klausner, K. Rao, and J.B. Harford. 1986. Exposure of K562 cells to anti-receptor monoclonal antibody OKT9 results in rapid redistribution and enhanced degradation of the transferrin receptor. *J. Cell Biol.* 102:951–958.

Welsh, M.J., and A.E. Smith. 1993. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. *Cell.* 73:1251–1254.

Wickner, S., M.R. Maurizi, and S. Gottesman. 1999. Posttranslational quality control: folding, refolding and degrading proteins. *Science.* 286:1888–1893.

Wilcox, C.A., K. Redding, R. Wright, and R.S. Fuller. 1992. Mutation of a tyrosine localization signal in the cytosolic tail of yeast Sec2 protease disrupts Golgi retention and results in default transport to the vacuole. *Mol. Biol. Cell.* 3:1353–1371.

Wilson, M.H., and L.E. Limbird. 2000. Mechanisms regulating the cell surface residence time of the α₂,δ-odenergic receptor. *Biochemistry.* 39:693–700.

Wolins, N., H. Bosshart, H. Kuster, and J.S. Bonifacino. 1997. Aggregation as a determinant of protein fate in post-Golgi compartments: role of the luminal domain of furin in lysosomal targeting. *J. Cell Biol.* 139:1735–1745.

Xiong, Y., E. Chong, and W.R. Skach. 1999. Evidence that endoplasmic reticulum (ER)-associated degradation of CFTR is linked to retrograde translocation from the ER membrane. *J. Biol. Chem.* 274:2616–2624.

Yang, Y., S. Janich, J.A. Cohn, and J.M. Wilson. 1993. The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. *Proc. Natl. Acad. Sci. USA.* 90:9480–9484.

Zhang, F., F. Kartner, and G.L. Lukacs. 1998. Limited proteolysis as a probe for arrested conformational maturation of the F508 CFTR. *Nat. Struct. Biol.* 5:180–183.

Zielenski, J., and L.C. Tsui. 1995. Cystic fibrosis: genotypic and phenotypic variations. *Annu. Rev. Genet.* 29:777–807.